



Living Cell Technologies Limited

PO Box 3014

Auburn VIC 3123

ABN: 14 104 028 042

Resignation of Director

ASX Announcement –24 August 2007, Melbourne, Australia:

Living Cell Technologies Ltd (ASX:LCT) wishes to advise that Mr Charles Macek has resigned as a Director of the company today.

Mr Macek has served LCT as a Director since March 2006.

The Board wishes to pay tribute to the contribution of Mr Charles Macek, who is resigning due to increasing time pressures from his other commitments.

“Charles has been a solid and supportive member of the LCT Board and has provided clear corporate governance and investment guidance. His input and involvement with the company has been highly valued.”

Yesterday, LCT announced the appointment of Dr David Brookes as an independent Australian Director to the Board.

Contact:

Dr Paul Tan Chief Executive Officer Mob: +61 402 716 984 Dir: +64 9 270 7941	Paris Brooke General Manager (AUS) Mob: +61 407 715 574 Tel: +61 3 9886 0247
---	---

About Living Cell Technologies: www.lctglobal.com

Living Cell is developing live cell therapy products to treat life threatening human diseases. The company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with type 1 diabetes, the company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The company entered clinical trials for its diabetes product in 2007.

LCT disclaimer

This document contains certain forward-looking statements, relating to LCT’s business, which can be identified by the use of forward-looking terminology, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management’s expectations regarding the approval and commercialization of product candidates could be affected by, among other things, unexpected clinical trial results; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects.